Wednesday, June 08, 2016 7:43:18 AM
http://cytosorb-therapy.com/the-therapy/case-of-the-week/
CytoSorb in pneumogenic septic shock after mitral valve reconstruction
Dr. Bastian Huschens, Dr. Ender Demircioglu, Department of Thoracic and Cardiovascular Surgery, University Hospital Essen
This case study reports on a 45-year-old female patient with mitral valve regurgitation III° and tricuspid valve regurgitation I-II° who underwent elective mitral valve reconstruction and then gradually deteriorated during her postoperative intensive care course.
Case presentation
On the 3rd postoperative day (POD) development of a ventilator-associated pneumonia culminating in pneumogenic sepsis with accompanying ARDS
Increased plasma levels of inflammatory parameters: PCT 29.4 ng/ml, CRP 21.2 mg/dl, elevated lactate 6.1 mmol/l
Antibiotic regimen: ciprofloxazin, tazobactam/piperacillin
Septic shock with multiple organ failure: hemodynamics (norepinephrine dose on the 2nd POD 1.5 µg/kg/min), lung, kidney, liver
Development of sepsis-associated liver dysfunction (bilirubin 3.9 mg/dl on the 1st POD and further increasing levels with a peak value on the 6th POD of 20 mg/dl)
Further deterioration of renal function, initially oliguric but trending towards decreasing excretion culminating in anuria and initiation of continuous renal replacement therapy (CVVH) on POD 5
Pre-ECMO therapy: kinetic positioning for 4 days
Initial stabilization of the circulatory situation (epinephrine dose on the 7th POD 0.05 µg/kg/min)
Second septic insult along with hemodynamic deterioration on POD 8 with 0.2 µg/kg/min and worsening liver failure (plasma bilirubin levels with peak value of 38.5 mg/dl, quick 24%, hepatic encephalopathy), lactate at 3.1 mmol/l
Escalation of antibiotic therapy from ciprofloxazin, tazobactam/piperacillin to imipenem/cilastatin
Due to acute renal- and respiratory failure, sharp increase in inflammatory markers and progressive need for vasopressors as well as further increase in bilirubin levels indicative of progressive liver failure, CytoSorb was installed into the CVVH circuit on the 8th POD
Treatment
8 CytoSorb treatment sessions for 24 hours each and a total treatment period of 8 days
CytoSorb was used in conjunction with citrate dialysis (Multifiltrate; Fresenius Medical Care) in CVVHDF mode
Blood flow rate: 100 ml/min
Anticoagulation: initially heparin, after recovery of liver function change to citrate
CytoSorb adsorber position: pre-hemofilter
Measurements
Demand for catecholamines
Inflammatory parameters (PCT, CRP)
Renal function (excretion)
Lactate
Bilirubin
Ammonia
Results
After implementation of CytoSorb there was an initial deterioration of the hemodynamic situation with increasing needs for catecholamines from 0.2 to 0.6 µg/kg/min for the first 24 hours, however there was a significant stabilization of hemodynamics in the further course of combined CVVH-CytoSorb treatment with a clear reduction in norepinephrine requirements. After 48 hours norepinephrine could be significantly reduced and was completely tapered off on the 12th POD
Reduction of inflammatory parameters during the course of treatments: PCT from 43.5 ng/ml on the first treatment day to 7.42 ng/ml on the 2nd and 1.35 ng/ml on the last treatment day; CRP from 31.8 mg/dl on the first treatment day to 21.3 mg/dl on the 2nd and 14.7 mg/dl on the last treatment day
Lactate from 1.3 mmol/l on the first treatment day to 4.6 mmol/l on the 2nd and 2.0 mmol/l on the last treatment day
Bilirubin from 25.6 mg/dl on the first treatment day to 17.2 mg/dl on the 2nd and 4.7 mg/dl on the last treatment day
Ammonia from 64 µg/dl on the first treatment day to 55 µg/dl on the 2nd, 135 µg/dl on the 4th, 201 µg/dl on the 5th and 6th treatment day and 47 µg/dl after the last treatment
No recovery of renal function
Patient Follow-Up
Patient still dialysis-dependent on POD 24
Regressive hepatic encephalopathy along with significant neurological improvement (vigilance)
Patient is free of catecholamines, complete regeneration of liver function including stabilization of coagulation disorder even without substitution
CPAP without pressure support, alternated with nightly BiPAP training
Transfer of the patient to a weaning clinic while awake, oriented and hemodynamically stable
Conclusions
The most obvious effect was the significant and rapid stabilization of liver function and neurological improvement
Acute phase of septic shock could be overcome surprisingly quickly
Clear stabilization and consolidation of hemodynamics and inflammatory mediators with CytoSorb
Handling of the adsorber was easy and safe
Recent CTSO News
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting • GlobeNewswire Inc. • 04/17/2024 11:00:00 AM
- CytoSorbents to Report Fiscal 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/06/2024 12:00:00 PM
- CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 10:20:45 PM
- Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients • GlobeNewswire Inc. • 01/17/2024 12:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/08/2024 08:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:49:02 PM
- CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation • GlobeNewswire Inc. • 12/28/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:35:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:33:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:31:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:30:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 02:15:22 PM
- CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering • GlobeNewswire Inc. • 12/13/2023 02:15:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/11/2023 09:10:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:10:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:20:25 PM
- CytoSorbents Reports Third Quarter 2023 Financial and Operational Results • GlobeNewswire Inc. • 11/09/2023 09:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:10:54 PM
- CytoSorbents to Report Third Quarter 2023 Operating and Financial Results • GlobeNewswire Inc. • 10/27/2023 11:00:00 AM
- CytoSorbents to Present at the 8th Annual Dawson James Conference • GlobeNewswire Inc. • 10/05/2023 11:00:00 AM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM